icon_heart_whiteicon_heart_whiteicon_heart_whiteicon_heart_white
  • Technology
  • Features
  • Applications
  • Licensing
  • ATCOR Medical

Homepage Latest

Published by Mark Kelly on September 9, 2019
Cardiovascular disease (CVD) is a global epidemic, compounded by diabetes and other chronic illnesses.
We Can Help

SphygomorCor® offers a better way to detect CVD earlier and target treatment for each individual patient.

Central blood pressure is the best predictor of cardiovascular risk.

SphygomorCor® is the industry standard for noninvasive central blood pressure (NcBP) and arterial stiffness - vital data that deliver deep, individual clinical insights.
Learn More
SphygomorCor® XCEL integrates seamlessly into standard clinical workflows. Noninvasive central blood pressure (NcBP) and other unique data can help physicians personalize medications and get patients to goal faster.
Learn More
SphygomorCor® by the numbers

All “Top 20 Hospitals” use SphygmoCor technology to measure central blood pressure (cBP)

1,400+ studies using the SphygmoCor technology have been published in peer-reviewed clinical publications.

8 out of Top 10 Pharma companies have used SphygmoCor technology in their clinical trials

Over 11,000 patients have been tested with SphygmoCor technology in pharmaceutical trials

Share
Sign up for our VITALITY newsletter
[ctct form="491" show_title="false"]

You can unsubscribe at any time

Subscribe
© 2020 ATCOR All Rights Reserved.
ATCOR Logo
PRIVACY   |  TERMS & CONDITIONS